Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.48 |
| ▸ | JAK1 | P23458 | 10/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | MELK | Q14680 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3374887 | 0.89 | JAK2 (0.47) | JAK2JAK1JAK3HDAC6HDAC1 | |
| SCHEMBL3375096 | 0.89 | JAK2 (0.54) | JAK2JAK1JAK3HDAC6HDAC1 | |
| SCHEMBL3374827 | 0.85 | JAK2 (0.47) | JAK2JAK1JAK3HDAC6HDAC1 | |
| SCHEMBL3376937 | 0.83 | JAK2 (0.50) | JAK2JAK1 | |
| SCHEMBL14563895 | 0.80 | JAK2 (0.70) | JAK2JAK1 | |
| SCHEMBL4102998 | 0.80 | JAK2 (0.46) | JAK2JAK1JAK3HDAC6HDAC1 | |
| SCHEMBL3377503 | 0.80 | JAK1 (0.43) | JAK2JAK1JAK3HDAC6HDAC1 | |
| SCHEMBL17957109 | 0.80 | JAK2 (0.68) | JAK2JAK1 | |
| SCHEMBL17957100 | 0.80 | JAK2 (0.68) | JAK2JAK1 | |
| SCHEMBL19808798 | 0.79 | JAK2 (0.70) | JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013173506-A2 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | WO | disclosed |
| WO-2010039939-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |